comparemela.com

Page 15 - Leonard Mazur News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Citius Pharmaceuticals, Inc Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing.

United statesIlanit allenLeonard mazurNovecite incCompany nasdaqDrug administrationExchange commissionDevelopment rd expensesCorporate communicationsPrnewswire citius pharmaceuticals incSecurities exchangeCitius pharmaceuticals incInvestor relations for citius pharmaceuticalsLicense applicationLido phaseHalo lido phase

Citius Pharmaceuticals, Inc Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update - Press Release

$48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023 International sites for Mino-Lok® Phase

United statesIlanit allenLeonard mazurDrug administrationExchange commissionDevelopment rd expensesCorporate communicationsSecurities exchangeInvestor relations for citius pharmaceuticalsCitius pharmaceuticals incLicense applicationCitius pharmaceuticalsLido phaseHalo lido phaseFast trackSecurities act

Citius Pharmaceuticals, Inc Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing.

United statesIlanit allenLeonard mazurNovecite incCompany nasdaqDrug administrationExchange commissionDevelopment rd expensesCorporate communicationsPrnewswire citius pharmaceuticals incSecurities exchangeCitius pharmaceuticals incInvestor relations for citius pharmaceuticalsLicense applicationLido phaseHalo lido phase

Citius Pharmaceuticals, Inc Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing.

United statesIlanit allenLeonard mazurCompany nasdaqDrug administrationExchange commissionPrnewswire citius pharmaceuticals incCorporate communicationsSecurities exchangeInvestor relations for citius pharmaceuticalsCitius pharmaceuticals incBiologics license applicationDrug evaluationCitius pharmaceuticalsFast trackSecurities act

Citius Pharmaceuticals, Inc Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing.

Ilanit allenLeonard mazurNovecite incCompany nasdaqDrug administrationExchange commissionPrnewswire citius pharmaceuticals incCorporate communicationsSecurities exchangeInvestor relations for citius pharmaceuticalsCitius pharmaceuticals incCitius boardCitius pharmaceuticalsPivotal phaseFast trackSecurities act

vimarsana © 2020. All Rights Reserved.